NCT03925636 (SCD_cDiff) is a NA clinical trial of Specific Carbohydrate Diet in Clostridium Difficile Infection, sponsored by David Suskind.

Who is sponsoring NCT03925636?

NCT03925636 is sponsored by David Suskind.

What drugs are being tested in NCT03925636?

Interventions in NCT03925636: Specific Carbohydrate Diet.

What condition does NCT03925636 study?

NCT03925636 studies Clostridium Difficile Infection, Diet Modification.

Is NCT03925636 still recruiting?

NCT03925636 is currently completed. Last updated 11 July 2022.

Last reviewed 2022-07-11 · How we verify

NCT03925636: SCD_cDiff

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Specific Carbohydrate Diet for Clostridium Difficile

Completed NA Last updated 11 July 2022

What this trial tests

NA trial testing Specific Carbohydrate Diet in Clostridium Difficile Infection in 4 participants. Completed in 1 March 2022.

Timeline

8 June 2016

Primary endpoint
1 March 2022

1 March 2022

Quick facts

Lead sponsor	David Suskind
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	8 June 2016
Primary completion	1 March 2022
Estimated completion	1 March 2022
Sites	1 location across United States

Drugs / interventions tested

Specific Carbohydrate Diet

Conditions studied

Clostridium Difficile Infection — all drugs for Clostridium Difficile Infection →
Diet Modification — all drugs for Diet Modification →

Sponsor

David Suskind

Who can join

Adults 18 Months to 21, any sex, with Clostridium Difficile Infection or Diet Modification. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators are doing this research study to answer questions about a nutritional therapy called the Specific Carbohydrate Diet (SCD) for children with active Clostridium Difficile Infection. For this study, the investigators will be looking to determine: 1. Is SCD effective for the treatment for Clostridium Difficile Colonization? 2. Is the SCD well tolerated?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Specific Carbohydrate Diet

Trials testing the same drug.

NCT04398550 — SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis · NA · unknown

Other recruiting trials for Clostridium Difficile Infection

Currently open trials in the same condition.

NCT07221370 — Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients · Phase 2, PHASE3 · recruiting
NCT06703918 — Study on Clostridium Difficile Infection in Infants · recruiting
NCT04305769 — Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) · Phase 2 · recruiting
NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation · NA · recruiting
NCT03562741 — Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03925636 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by David Suskind
Last refreshed: 11 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03925636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing